Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 186 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Adult
Interventions
SM08502
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Conditions
Socket Sealing, Free Gingival Graft, Collagen Membrane
Interventions
Socket preservation
Procedure
Lead sponsor
Universidade Salgado de Oliveira
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Kidney Transplant Failure
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2004 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Recruiting No phase listed Observational

The PREDICT Registry:

NCT03448926
Conditions
DCIS, Stage 0 Breast Cancer, Ductal Breast Carcinoma In Situ
Interventions
Treatment recommendation surveys, 7-gene biosignature
Other · Device
Lead sponsor
PreludeDx
Industry
Eligibility
30 Years to 85 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
30
States / cities
Scottsdale, Arizona • La Jolla, California • San Mateo, California + 25 more
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma
Interventions
Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 40 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
186
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
Conditions
Basal Cell Carcinoma
Interventions
Two photon fluorescence microscopy imaging
Device
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Victor, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Osseodensification and Implant Survival and Success

NCT04741594
Conditions
Missing Teeth
Interventions
Densah
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies
Interventions
CYTALUX™ (pafolacianine), 1788 4K Camera System with Advanced Imaging Modality
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Cervical Cancer, HIV
Interventions
DeepDOF Images
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 49 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions
Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
Drug · Radiation · Procedure + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Stanford, California + 28 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

BCT-HA Kit for Dehydrated and Wrinkled Skin

NCT05514834
Conditions
Rhytides, Wrinkle
Interventions
Cellular Matrix TM BCT-HA Kit (ref. BCT-HA-3), PRP Only, Placebo
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Oral Dysplasia, Leukoplakia Oral, Leukoplakia
Interventions
Imiquimod (topical use)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional Radiofrequency for Reduction of Surgical Scar Formation

NCT05897723
Conditions
Surgical Incision
Interventions
Fractional Radiofrequency
Device
Lead sponsor
Venus Concept
Industry
Eligibility
21 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
Interventions
Vicinium
Drug
Lead sponsor
Sesen Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Tallahassee, Florida • Baltimore, Maryland • Lawrenceville, New Jersey + 5 more
Completed Not applicable Interventional Results available

Donors After Circulatory Death Heart Trial

NCT03831048
Conditions
Heart Transplant
Interventions
OCS Heart System, Cold Storage
Device · Other
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Conditions
Barrett's Esophagus
Interventions
Confocal laser endomicroscopy (pCLE)
Device
Lead sponsor
Virendra Joshi
Other
Eligibility
19 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Kenner, Louisiana • New Orleans, Louisiana
No Longer Available No phase listed Expanded access

Expanded Access Program With Nivolumab to Treat Melanoma

NCT02142218
Conditions
Stage III (Unresectable) or Stage IV Advanced Melanoma
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Timeline
2014 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Encinitas, California • Washington D.C., District of Columbia + 19 more
Conditions
Facial Rejuvenation
Interventions
755nm Laser with Cap Array
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Sacramento, California
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Conditions
Benign Neoplasm, Malignant Neoplasm
Interventions
Indocyanine green, SPY-PHI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Transplant Failure, Kidney Function Issue
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2000 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 2 more
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Completed Not applicable Interventional Results available

Trial Comparing 19 and 25-gauge EUS-FNA Needles

NCT01677312
Conditions
Cancer of Pancreas, Pancreatic Neoplasm
Interventions
Pancreatic Biopsy, Histological Samples
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Orlando, Florida